Follow-up on health outcomes in patients with histiocytic disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the long-term health impacts of histiocytic disorders, including chronic health conditions, psychological issues, and overall quality of life. By utilizing a retrospective cohort design, the study will gather data from approximately 6000 patients diagnosed with various histiocytic disorders through validated questionnaires. The focus is on understanding the burden of morbidity and mortality associated with these conditions, particularly in relation to healthcare utilization and the risk of secondary malignancies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* diagnosis of histiocytic disorder at any age

  1. Langerhans cell histiocytosis,
  2. Erdheim-Chester disease,
  3. Rosai-Dorfman disease,
  4. Xanthogranuloma,
  5. Mixed histiocytosis
  6. Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma)
  7. Hemophagocytic lymphohistiocytosis

Exclusion Criteria:

* None

Where it's running

• University of Alabama at Birmingham
  Birmingham, Alabama, United States Recruiting

Study contacts

• Principal investigator: Gaurav Goyal, MD — University of Alabama at Birmingham
• Study coordinator: Gaurav Goyal, MD
• Email: histio@uabmc.edu
• Phone: 1-866-438-1640

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using cobimetinib to treat refractory Langerhans cell histiocytosis and other histiocytic disorders

  This study is testing if a drug called cobimetinib can help people with hard-to-treat Langerhans cell histiocytosis and other similar disorders feel better.

  Recruiting at 10 sites Phase 2 Baylor College of Medicine · Phoenix, Arizona and 11 other locations · NCT04079179

• Imaging of tumors using a specific PET scan agent

  This study is testing a new PET scan agent to see if it can help find and understand tumors in patients with different blood cancers and solid tumors.

  Recruiting Early Phase 1 Memorial Sloan Kettering Cancer Center · New York, New York · NCT05093335

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Low-dose cytarabine combined with thalidomide for adults with newly diagnosed LCH

  This trial tests whether combining low-dose cytarabine with thalidomide is safe and effective for adults newly diagnosed with multisystem or multifocal Langerhans cell histiocytosis.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07187193

• Lenalidomide plus dexamethasone for Rosai‑Dorfman disease

  This trial will try lenalidomide combined with dexamethasone to treat adults with Rosai‑Dorfman disease.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07187167

• Targeted treatment for Langerhans Cell Histiocytosis using trametinib

  This study is testing if trametinib, a new targeted therapy, can help children with Langerhans Cell Histiocytosis feel better and avoid the harsh side effects of traditional chemotherapy.

  Recruiting Phase 2 Cook Children's Health Care System · Fort Worth, Texas · NCT06582745

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.